WHO is creating new guidelines to stop lab leaks and the development of bioweapons. But scientists, focused on projects and funding, see only the benefits, rather than the risks, of their work, report warns.
Cash-rich pharma is dropping any pretence they are buying cash-strapped biotech for access to innovative technology. What it wants is products. Let’s hope it doesn’t suffocate the feedstock of innovation in the process.